Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat

Autor: Caroline E. Rasmussen, Jette Nowak, Julie M. Larsen, Emma Moore, David Bell, Kai Chiu Liu, Nanna Skall Sorensen, Wendela A. Kappers, Thomas Krogh-Meibom, Hanne Offenberg

Publikováno v: Journal of Toxicology, Vol 2017 (2017)

Turoctocog alfa pegol (N8-GP) is a glycoPEGylated human recombinant factor VIII for the treatment of hemophilia A. The safety profile of rFVIII, and polyethylene glycols (PEG) technology, is well-established. Conducting long-term toxicity studies in

Externí odkaz: https://doaj.org/article/ee7952f1805443caa9153dee89120cad

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Autor: Timo K van den Berg, Hugo Olsman, Hanke L Matlung, Katka Franke, Imke Lodewijks, Lilian Driessen-Engels, Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)

Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howev

Externí odkaz: https://doaj.org/article/b070a5b304cf452fb3bfdad0492340e0

Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

Autor: Wim H.A. Dokter, Miranda M.C. van der Lee, Ruud Ubink, Wendela A. Kappers, Marion Blomenröhr, Daniëlle van Wijk, Dirk H. Glaudemans, Jan Schouten, Ruud G.E. Coumans, Fred A. Dijcks, Aloys Sesink, Monique A.J. van der Vleuten, Myrthe Rouwette, Tinie van Boekel, Marloes E.M. Stokman, Ellen Mattaar-Hepp, Kim Berentsen, Désirée Damming, Inge A.T. Hermens, Daniëlle C.H. Jacobs, Patrick G. Groothuis

MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely overexpressed in various solid cancer types, is an attractive target for the development of antibody-based therapeutics. BYON3521 is a novel site-specific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cccdcc8e13ae8eaff0b9bd9148870aa
https://doi.org/10.1158/1535-7163.c.6653598.v1

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells

Autor: Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter, Timo K van den Berg

Publikováno v: van Helden, M J, Zwarthoff, S A, Arends, R J, Reinieren-Beeren, I M J, Paradé, M C B C, Driessen-Engels, L, de Laat-Arts, K, Damming, D S, Santegoeds-Lenssen, E W H, van Kuppeveld, D W J, Lodewijks, I, Olsman, H, Matlung, H L, Franke, K, Mattaar-Hepp, E, Stokman, M E M, de Wit, B, Glaudemans, D H R F, van Wijk, D E J W, Joosten-Stoffels, L, Schouten, J, Boersema, P J, van der Vleuten, M, Sanderink, J W H, Kappers, W A, van den Dobbelsteen, D, Timmers, M, Ubink, R, Rouwendal, G J A, Verheijden, G, van der Lee, M M C, Dokter, W H A & van den Berg, T K 2023, ' BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells ', Journal for Immunotherapy of Cancer, vol. 11, no. 4, jitc-2022-006567 . https://doi.org/10.1136/jitc-2022-006567

BackgroundPreclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f6e6308ed606888d418126a12792c8
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d

Diazinon Is Activated by CYP2C19 in Human Liver

Autor: Alan R. Boobis, Robert Edwards, Wendela A. Kappers, Stephen Murray

Publikováno v: Toxicology and Applied Pharmacology. 177:68-76

Phosphorothioate compounds are used throughout the world as agricultural and domestic pesticides. Here, the activation of the phosphorothioate diazinon to diazoxon in human liver is described. In an initial study using three human liver microsomal sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67478669f5e5d302e20f56fda06447e0
https://doi.org/10.1006/taap.2001.9294